We also identify a compact set of gene changes upon ErbB2 inhibition and demonstrate strong overlap with EGFR-driven cancers and further identify PHLDA1 as a novel negative feedback inhibitor and candidate tumor suppressor in ErbB2-dependent cancers. Here, EGFR is linked to neoplasm.